Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Telavive
Ronit El Hasid
38 anos de experiência
Clínica certificada :
| Israel | Turquia | Áustria | |
| Teste de Sangue para Marcadores Tumorais | de $100 | de $100 | de $100 |
A Bookimed não adiciona taxas extras aos preços de Teste de Sangue para Marcadores Tumorais. As tarifas vêm das listas oficiais das clínicas. O pagamento é feito diretamente na clínica na chegada.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais em Teste de Sangue para Marcadores Tumorais e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de Teste de Sangue para Marcadores Tumorais.
A Clínica Assuta é o maior centro médico privado de Israel. O hospital especializa-se em oncologia, ortopedia, neurocirurgia, cirurgia cardíaca e tratamento de infertilidade. 13% de todas as operações no país são realizadas na Assuta, o que a torna um centro cirúrgico líder.
Pela qualidade e segurança no tratamento, o hospital recebeu a acreditação americana da Joint Commission International.
Anualmente, os médicos da rede Assuta realizam mais de 92.000 operações, 685.000 procedimentos diagnósticos e 16.000 ciclos de FIV.
O médico é o chefe do Departamento de Oncohematologia e Oncologia Pediátrica no Hospital Infantil Dana Dwek. Especializando-se em transplantes de medula óssea e sangue do cordão umbilical para crianças, o médico realizou mais de 300 transplantes. Com uma forte presença acadêmica, o médico publicou 50 artigos e apresentou 40 relatórios em várias conferências médicas. O médico é membro da Associação Americana de Hematologia e da Sociedade Israelense de Hemato-oncologia Pediátrica, e praticou no Hospital City of Hope em Los Angeles e em vários centros médicos em Israel.<\/p>
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.